13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer; breast cancer Cell culture studies identified a defactinib-based FAK degrader compound that could help treat prostate cancer and triple-negative breast cancer (TNBC). The compound consists of an analog of the FAK inhibitor...
18:01 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Seizures Fruit fly studies suggest inhibiting FAK, integrin β, TLN1, TNS1 or MMP1 could help treat seizures. In a Drosophila model of mechanically induced seizures, an astrocyte-specific RNAi screen identified four genes encoding components...
21:08 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Verastem's defactinib combo leads to PR in pancreatic cancer

Verastem Inc. (NASDAQ:VSTM) reported data from 15 evaluable patients with refractory solid tumors in the dose-escalation portion of a Phase I trial showing that defactinib (VS-6063) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co....
21:24 , Nov 10, 2017 |  BC Week In Review  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
23:02 , Nov 3, 2017 |  BC Extra  |  Company News

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd. (Tel Aviv:BLRX;...
21:54 , Sep 8, 2017 |  BioCentury  |  Finance

Verastem’s value play

Verastem Inc. (NASDAQ:VSTM) has parlayed a small gamble on Phase III asset duvelisib into a double-digit stock bump and what could become the company’s first commercial product. Verastem soared $1.08 (28%) to $4.92 on Sept....
17:21 , May 26, 2017 |  BC Week In Review  |  Clinical News

Verastem reports Phase II data for defactinib in MPM

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago next month, Verastem Inc. (NASDAQ:VSTM) reported data from a Phase II trial in 30 patients with malignant pleural mesothelioma (MPM)...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor associated fibroblast levels of integrin α 5 β 1 , phosphorylated FAK , phosphorylated SMAD2 and phosphorylated SMAD3 could help predict outcomes in pancreatic ductal adenocarcinoma (PDAC) and renal cell carcinoma...